Previous 10 | Next 10 |
Epizyme, Inc. (EPZM) Q4 2021 Earnings Conference Call March 1, 2022 8:30 AM ET Company Participants Grant Bogle – President and Chief Executive Officer Shefali Agarwal – Executive Vice President, Chief Medical and Development Officer Conference Call Participants Joseph Thome ...
Epizyme press release (NASDAQ:EPZM): Q4 GAAP EPS of -$0.49 misses by $0.08. Revenue of $11.6M (+38.1% Y/Y) misses by $8.82M. Revised 2022 Financial Guidance: 2022 total non-GAAP adjusted operating expenses are now expected to be between $160-180 million, compared to the prior guidance of $170...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.6 Million for 4Q 2021; $30.9 Million for FY 2021 $85 Million in Gross Proceeds Raised in January 2022 Public Offering, Combined with Recent Expense Reductions Announced Today, Extends Cash Runway into...
Epizyme (NASDAQ:EPZM) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open. The consensus EPS Estimate is -$0.48 and the consensus Revenue Estimate is $20.42M (+143.1% Y/Y). Over the last 1 year, EPZM has beaten EPS estimates 75% of the time and has beaten re...
Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a...
Shares of biopharmaceutical company Epizyme (NASDAQ: EPZM) rose 32.1% this week, according to data from S&P Global Market Intelligence . The stock, which closed at $1.06 a share last Friday, opened at that same price on Monday before rising to as high as $1.49 a share on Wed...
Are These 3 Under $4 Penny Stocks Worth Watching Today? With another day of trading penny stocks and blue chips off to an interesting start, there is a lot for investors to consider right now. While the market began strong for penny stocks , we quickly witnessed a turnaround by midd...
Gainers: Palisade Bio (NASDAQ:PALI) +23%. Pharming Group (NASDAQ:PHAR) +14%. Entasis Therapeutics (NASDAQ:ETTX) +13%. Epizyme (NASDAQ:EPZM) +11%. IceCure Medical (NASDAQ:ICCM) +10%. Losers: LogicBio Therapeutics (NASDAQ:LOGC) -50%. Pardes Bios...
MDJM (NASDAQ:MDJH) +64%. The OLB Group OLB +25% reports $1.35B in transaction value post CBD Merchants acquisition. Advanced Micro Devices AMD +13% on Q4 results. Xilinx (NASDAQ:XLNX) +12%. Capri Holdings CPRI +12% on Q3 results. IceCure Medical (NASDAQ:ICCM) +11%. Arrival...
One of the steepest decliners in the biotech sector Thursday was Epizyme (NASDAQ: EPZM) . The cancer-focused biotech saw its shares plummet 44% in value that day, on news of a dilutive secondary stock issue. Epizyme announced that it is floating nearly 56.7 million shares of its...
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...